CytoDyn Company Description

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications.

It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19.

The company’s leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer.

The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

CytoDyn Inc.

Country	United States
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	13
CEO	Jacob Lalezari

Contact Details

Address: 1111 Main Street Vancouver, Delaware 98660 United States
Phone	360 980 8524
Website	cytodyn.com

Stock Details

Ticker Symbol	CYDY
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	June - May
Reporting Currency	USD
ISIN Number	US23283M1018
SIC Code	2836

Key Executives

Name	Position
Dr. Jacob P. Lalezari M.D.	Chief Executive Officer
Robert E. Hoffman B.B.A., CPA	Chief Financial Officer
Tyler Blok	Chief Legal Officer and Corporate Secretary
Dr. Bernie Cunningham P.M.P., Ph.D.	Vice President of Operations
Dr. Cyrus Arman M.B.A., Ph.D.	Senior Vice President of Business Operations
Dr. Scott Hansen Ph.D.	Head of Research and Basic Science
Dr. Max Lataillade D.O., M.P.H.	Senior Vice President and Head of Clinical Development
Cristina De Leon	Investors